Base de dados : LILACS
Pesquisa : D09.400.420.110 [Categoria DeCS]
Referências encontradas : 118 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 12 ir para página                         

  1 / 118 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-887013
Autor: AlGhamdi, Khalid M; Kumar, Ashok; Ashour, Abdelkader E; AL-Rikabi, Ammar C; AlOmrani, Abdullah Hasan; Ahamed, Shaik Shaffi.
Título: Vascular sclerosing effects of bleomycin on cutaneous veins: a pharmacopathologic study on experimental animals
Fonte: An. bras. dermatol;92(4):484-491, July-Aug. 2017. tab, graf.
Idioma: en.
Projeto: King Abdulaziz City for Science and Technology.
Resumo: Abstract: Background: Varicose veins and the complications of venous disease are common disorders in humans. Objective: To study the effects of bleomycin as a potential new sclerosing agent and its adverse events in treating varicose veins. Methods: Bleomycin-loaded liposomes 0.1ml was injected in the dorsal ear veins of white New Zealand rabbits. Sodium tetradecyl sulfate was used as a positive control. Normal saline was used as negative control. The blood vessels of the treated ears were photographed before and at one hour and two, eight and 45 days after treatment. Biopsies from the treated areas were obtained for histological examination. Blood samples were collected to determine any possible toxicity. Results: Bleomycin by itself was ineffective; therefore, liposomes were used as a vector to deliver bleomycin to the vein lumen. Subsequently, bleomycin started showing its sclerosing effects. Toxicity monitoring showed no apparent hematologic, pulmonary, hepatic or renal toxicities. This study revealed that bleomycin induced vasculitis, which led to vascular occlusion, which was observed on day 1 and day 8. No bleomycin-related injury was noted by histopathological examination of lung sections. The calculation of the lung/body weight coefficient indicated that edema was present in the experimental groups compared with the negative and positive controls. Study limitations: Relatively small number of experimental animals used. Conclusions: This study showed that bleomycin-loaded liposomes were able to induce vasculitis and vascular occlusion without any toxicity or complications. It might be useful, hence, to treat patients suffering from Varicose veins and other ectatic vascular diseases with this agent.
Descritores: Soluções Esclerosantes/farmacologia
Tetradecilsulfato de Sódio/administração & dosagem
Varizes/terapia
Bleomicina/farmacologia
Escleroterapia/métodos
Antibióticos Antineoplásicos/administração & dosagem
-Soluções Esclerosantes/administração & dosagem
Soluções Esclerosantes/efeitos adversos
Vasculite/induzido quimicamente
Vasculite/tratamento farmacológico
Veias/efeitos dos fármacos
Bleomicina/administração & dosagem
Modelos Animais de Doenças
Avaliação Pré-Clínica de Medicamentos
Injeções Intravenosas
Lipossomos
Limites: Animais
Coelhos
Responsável: BR1.1 - BIREME


  2 / 118 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1026344
Autor: Zarza Escobar, Jonathan; Sanz, Luis Sebastian; Agnesio, Héctor Rodolfo; Canteros, Lelia Andrea; Oviedo, Nelson Enrique.
Título: Tratamiento esclerosante del linfangioma facial. Presentación de un caso / Sclerotherapic treatment of facial lymphangioma
Fonte: Prensa méd. argent;105(1):41-46, mar 2019.
Idioma: es.
Resumo: This article details the treatment of lymphangioma of the face with intralesional bleomycin: with a case report and literature review. Surgical treatment of lymphangioma of the face is a difficult task to achieve, due to close vicinity of the lesion to the facial nerve and possibility of scar tissue formation. Inefficient surgical removals generally will give rise to high recurrence rates because of infiltrative and diffuse extension of the lesion. However, complete cure has been described by non-surgical methods with intralesional bleomycin injection under ultrasonographic guidance. Lymphangioma is a rare congenital malformation of the lymphatic system, frequently seen in the head and neck. Percutaneous sclerotherapy of lymphangioma involves the injection of sclerosing substances into the lymphangioma. This study aims to evaluate the effectiveness of intralesional bleomycin sclerotherapy in the treatment of lymphangioma, and to determine the incidence of complications in the treatment. Intralesional bleomycin therapy was very effective in the treatment of lymphangioma. Bleomycin administered as intralesional injection was found to be safe as there was no lesions complicating or side effects observed in the study.
Descritores: Bleomicina/uso terapêutico
Escleroterapia
Traumatismos Faciais/terapia
Linfangioma/terapia
Limites: Seres Humanos
Feminino
Adolescente
Tipo de Publ: Relatos de Casos
Revisão
Estudo Observacional
Responsável: AR392.1 - Biblioteca


  3 / 118 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: lil-725919
Autor: Antonio, João Roberto; Pellizzari, Fernanda Ometto; Antonio, Carlos Roberto.
Título: Associação de técnicas para manejo efetivo dos queloides / Association of techniques for effective management of keloids
Fonte: RBM rev. bras. med;71(n.esp.g2), jun. 2014.
Idioma: pt.
Resumo: Queloides constituem uma proliferação anormal de fibroblastos após injúria da pele que ultrapassam bordas da ferida, causando aparência inestética e grande prejuízo à qualidade de vida destes pacientes. Atualmente não há uma terapêutica combinada eficaz para redução das massas queloidianas, inibindo sua recidiva. Neste trabalho apresentamos uma série de casos tratados com uma associação de técnicas (excisão cirúrgica pela técnica de shaving, injeção intralesional de corticosteroide e/ou bleomicina, aplicação de placa de gel de silicone, luz intensa pulsada, laser de CO2 fracionado, laser Nd:YAG, laser Erbium:Glass e LED vermelho e infravermelho), atuando na fisiopatologia do queloide, que demonstraram resultados satisfatórios e duradouros...
Descritores: Bleomicina
Lasers
Queloide
Triancinolona
Limites: Seres Humanos
Tipo de Publ: Revisão
Responsável: BR12.1 - Biblioteca Setorial da Ciências da Saúde


  4 / 118 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: lil-582740
Autor: Cortez, Afonso José Pereira; Dulley, Frederico Luiz; Saboya, Rosaura; Mendrone Júnior, Alfredo; Amigo Filho, Ulisses; Coracin, Fabio Luiz; Buccheri, Valéria; Linardi, Camila da Cruz Gouveia; Ruiz, Milton Artur; Chamone, Dalton de Alencar Fischer.
Título: Autologous hematopoietic stem cell transplantation in classical Hodgkin's lymphoma
Fonte: Rev. bras. hematol. hemoter;33(1):10-14, Feb. 2011. graf, tab.
Idioma: en.
Resumo: BACKGROUND: Hodgkin's lymphoma has high rates of cure, but in 15 percent to 20 percent of general patients and between 35 percent and 40 percent of those in advanced stages, the disease will progress or will relapse after initial treatment. For this group, hematopoietic stem cell transplantation is considered one option of salvage therapy. OBJECTIVES: To evaluate a group of 106 patients with Hodgkin's lymphoma, who suffered relapse or who were refractory to treatment, submitted to autologous hematopoietic stem cell transplantation in a single transplant center. METHODS: A retrospective study was performed with data collected from patient charts. The analysis involved 106 classical Hodgkin's lymphoma patients who were consecutively submitted to high-dose chemotherapy followed by autologous transplants in a single institution from April 1993 to December 2006. RESULTS: The overall survival rates of this population at five and ten years were 86 percent and 70 percent, respectively. The disease-free survival was approximately 60 percent at five years. Four patients died of procedure-related causes but relapse of classical Hodgkin's lymphoma after transplant was the most frequent cause of death. Univariate analysis shows that sensitivity to pre-transplant treatment and hemoglobin < 10 g/dL at diagnosis had an impact on patient survival. Unlike other studies, B-type symptoms did not seem to affect overall survival. Lactic dehydrogenase and serum albumin concentrations analyzed at diagnosis did not influence patient survival either. CONCLUSION: Autologous hematopoietic stem cell transplantation is an effective treatment strategy for early and late relapse in classical Hodgkin's lymphoma for cases that were responsive to pre-transplant chemotherapy. Refractory to treatment is a sign of worse prognosis. Additionally, a hemoglobin concentration below 10 g/dL at diagnosis of Hodgkin's lymphoma has a negative impact on the survival of patients after transplant. As far as we know this relationship has not been previously reported.
Descritores: Transplante Autólogo
Vimblastina
Bleomicina
Doença de Hodgkin
Doxorrubicina
Estudos Retrospectivos
Transplante de Células-Tronco Hematopoéticas
Dacarbazina
Limites: Seres Humanos
Masculino
Feminino
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM


  5 / 118 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: biblio-898956
Autor: Jaime-Pérez, José Carlos; Gamboa-Alonso, Carmen Magdalena; Padilla-Medina, José Ramón; Jiménez-Castillo, Raúl Alberto; Olguín-Ramírez, Leticia Alejandra; Gutiérrez-Aguirre, César Homero; Cantú-Rodríguez, Olga Graciela; Gómez-Almaguer, David.
Título: High frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of experience in a Latin American center
Fonte: Rev. bras. hematol. hemoter;39(4):325-330, Oct.-Dec. 2017. tab.
Idioma: en.
Resumo: Abstract Background: Reports dealing with clinical outcomes of classical Hodgkin's lymphoma in low- to middle-income countries are scarce and response to therapy is poorly documented. This report describes the characteristics and clinical outcomes of patients with classical Hodgkin's lymphoma from a single institution in Latin America. Method: A retrospective study was conducted over ten years of patients with classical Hodgkin's lymphoma treated at a referral center. Progression-free and overall survival rates were estimated by Kaplan-Meier analysis. The univariate Cox regression model was used to estimate associations between important variables and clinical outcomes. Main results: One hundred and twenty-eight patients were analyzed. The mean age was 28.5 years. The five-year progression-free and overall survival were 37.3% and 78.9%, respectively. Of the whole group, 55 (43%) were primary refractory cases. Only 39/83 (47%) patients with advanced disease vs. 34/45 (75.6%) in early stages (p-value = 0.002) achieved complete remission. Those with advanced disease had a five-year overall survival of 68.7% vs. 91.8% for early disease (p-value = 0.132). Thirty-one patients relapsed (24.2%) and 20 (64.5%) received a transplant. The hazard ratio for progression with bone marrow infiltration was 2.628 (p-value = 0.037). For death, an International Prognostic Score ≥4 had a hazard ratio of 3.355 (p-value = 0.050) in univariate analysis. Two-thirds of classical Hodgkin's lymphoma patients diagnosed at advanced stages had a low progression-free survival but an overall survival similar to high-income countries. Conclusion: Patients diagnosed with classical Hodgkin's lymphoma in Northeastern Mexico had a significantly low progression-free survival rate and presented with advanced disease, underscoring the need for earlier diagnosis and improved contemporary therapeutic strategies in these mainly young productive-age Hodgkin's lymphoma patients.
Descritores: Vincristina
Bleomicina
Doença de Hodgkin
Doxorrubicina
Taxa de Sobrevida
Dacarbazina
América Latina
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM


  6 / 118 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-843000
Autor: Karlen, Hugo; Martín, Vanina; Quadrelli, Silvia.
Título: Uso del PET-TC en toxicidad pulmonar por bleomicina / Use of PET-CT in pulmonary toxicity by bleomycin
Fonte: Rev. am. med. respir;16(3):271-272, set. 2016. ilus.
Idioma: es.
Resumo: Paciente masculino de 63 años, refiere disnea mMRC 2 y tos seca de 15 días de evolución. ExTabaquista de 60 paq/año. Recibió dos semanas antes 5° ciclo con bleomicina, doxorubicina, vinblasina y dacarbazine por Linfoma de Hodking. Presenta rales crepitantes bilaterales, predominio basal. Sat.O2 94%, afebril
Descritores: Bleomicina
Toxicidade
Pneumopatias
Responsável: AR423.1 - Biblioteca


  7 / 118 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-871489
Autor: Silva, Vanessa Martins da.
Título: Relevância do fibroblasto no remodelamento parenquimatoso pulmonar em modelos experimentais de fibrose induzida por bleomicina e 3-5-di-tert-4-hidroxitolueno / Relevance of fibroblasts in lung parenchymal remodeling in experimental models of bleomycin and 3-5-di-tert-4-hydroxytoluene-induced fibrosis.
Fonte: São Paulo; s.n; 2015. [156] p. ilus, graf, tab.
Idioma: pt.
Tese: Apresentada a Universidade de São Paulo. Faculdade de Medicina para obtenção do grau de Doutor.
Resumo: A remodelação do epitélio e do mesênquima subjacente tem um papel crucial na patogênese da fibrose pulmonar experimental. A iniciação, gravidade e distribuição de fibrose varia entre os diferentes agentes químicos. Estudos recentes indicaram que o envolvimento epitelial, a expressão de proteínas reguladoras do epitélio, ativação endotelial, estresse do retículo endoplasmático, a ativação de fibroblastos e acumulação de diferentes tipos de colágeno, pode ser específica em lesão causadas por diferentes agentes químicos. Neste estudo, comparou-se a fibrose pulmonar induzida por bleomicina (BLM) e hidroxitolueno butilado (BHT). Envolvimento epitelial, proteínas reguladoras, ativação endotelial e de fibroblastos foram quantitativamente avaliados pela densidade de células alveolares, expressão de telomerase, endotelina-1 (ET-1), fator de crescimento vascular (VEGF), fator de transformação do crescimento beta (TGF-beta) e do fator de crescimento de fibroblastos básico (bFGF). Estresse celular em células epiteliais alveolares do tipo 2 (AEC II) e fibroblastos, eventualmente, responsáveis pela gênese da fibrose pulmonar, foram investigados por microscopia eletrônica. Os colágenos do tipo I (Col I), III (Col III) e V (Col V) foram caracterizados e quantificados por imunofluorescência. A quantidade de colágeno pulmonar e alterações histológicas fibróticas foram significativamente aumentadas nos grupos BLM e BHT em relação aos controles, com diferença significativa entre a resposta fibrótica precoce e tardia. A densidade AEC II, a expressão da telomerase, ET-1, VEGF, TGF-beta e bFGF foram significativamente maiores nos grupos BLM e BHT do que em pulmões dos grupos controles, com diferença significativa entre a fase precoce e tardia da resposta fibrótica. Mitocôndrias anormais e estresse do retículo endoplasmático em AEC II e fibroblastos foram encontrados em ambos os grupos fibróticos. Aumento no acumulo de fibras de Col I, III e V, foram encontradas no interstício...

Epithelial and underlying mesenchyme remodeling have a critical role in the pathogenesis of experimental pulmonary fibrosis. The initiation, distribution and severity of fibrosis varies among different chemical agents. Recent studies have indicated that epithelial involvement, expression of epithelial regulatory proteins, endothelium activation, endoplasmic reticulum stress, fibroblast activation and accumulation of different types of collagen may be specific in various chemical agents of injury. In this study, bleomycin (BLM) and Butylated hydroxytoluene (BHT)-induced pulmonary fibrosis in mice were compared. Epithelial involvement, regulatory proteins, endothelium and fibroblast activation were quantitatively evaluated by alveolar cells density, telomerase, endothelin-1 (ET-1), Vascular endothelial growth factor (VEGF), Transforming growth factor beta (TGF-beta) and basic fibroblast growth factor (bFGF) expression. Cellular stress in type 2 alveolar epithelial cells (AEC II) and fibroblasts, eventually responsible by generating lung fibrosis, were investigated by electron microscopy. We characterized and quantified collagen type I (Col I), III (Col III) and V (Col V) by immunofluorescence. Lung collagen content and fibrotic histological changes were significantly increased in BLM and BHT models compared to control with significant difference between early and late fibrotic response. AEC II density, telomerase expression, ET-1, VEGF, TGF-beta and bFGF were significantly higher than control lungs with significant difference between early and late BLM and BHT fibrotic response. Abnormal mitochondria and endoplasmic reticulum in AEC II and fibroblasts was found in both groups of chemical agents. Increased of Col I, Col III and V fibers accumulation was found in the lung interstitium after BLM and BHT instillation. The expression of TGF-beta1 and alfa smooth muscle actin (alfa-SMA) gene was significantly increased in both model of pulmonary fibrosis. Activated...
Descritores: Remodelação das Vias Aéreas
Bleomicina
Hidroxitolueno Butilado
Células Epiteliais
Matriz Extracelular
Fibroblastos
Camundongos
Fibrose Pulmonar
Reação em Cadeia da Polimerase em Tempo Real
Fator de Crescimento Transformador beta
Limites: Animais
Masculino
Camundongos
Responsável: BR66.1 - Divisão de Biblioteca e Documentação
BR66.1


  8 / 118 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-835876
Autor: Saavedra R, Daniela; Matamala C, Ana María; Feldman F, Marcos.
Título: Dermatitis flagelada por bleomicina / Bleomycin-induced flagellate dermatitis
Fonte: Rev. chil. dermatol;29(1):70-70, 2013. ilus.
Idioma: es.
Descritores: Antibióticos Antineoplásicos/efeitos adversos
Bleomicina/efeitos adversos
Erupção por Droga/etiologia
-Clobetasol/uso terapêutico
Erupção por Droga/tratamento farmacológico
Hiperpigmentação/induzido quimicamente
Neoplasias Testiculares/tratamento farmacológico
Limites: Seres Humanos
Masculino
Adulto
Tipo de Publ: Relatos de Casos
Responsável: CL1.1 - Biblioteca Central


  9 / 118 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: lil-781803
Autor: Langhi, Julieta; Loriente, Diego Martin; Fondati, Fiorella; García, Sandra; Della Giovanna, Patricia.
Título: Dermatitis flagelada: nuestra experiencia / Flagellate dermatitis: our experience
Fonte: Dermatol. argent;21(3):197-201, 2015. ilus.
Idioma: es.
Resumo: La dermatitis flagelada es una entidad caracterizada por la presencia de máculas eritematopigmentadasde disposición lineal, localizadas a predominio del tronco. Descrita inicialmente como reacción adversa a la bleomicina, existen comunicaciones de otros fármacos implicados. También se la ha observado por ingesta de hongos shiitake y en el contexto de la dermatomiositis. Presentamos seis pacientes con clínica e histopatología compatibles con dermatitis flagelada:cuatro en tratamiento quimioterápico con bleomicina (tres mujeres y un hombre, de entre 20 y 40 años; con diagnóstico de linfoma Hodgkin, coriocarcinoma uterino y seminoma testicular). El quinto caso corresponde a una mujer de 46 años, con diagnóstico de LES que desarrolló las lesiones luego de recibir azatioprina. Y el sexto paciente masculino, de 60 años, que presentó una dermatitis flagelada en el contexto de una dermatomiositis amiopática...
Descritores: Bleomicina
Doença de Hodgkin/diagnóstico
-Azatioprina
Dermatomiosite
Limites: Seres Humanos
Masculino
Adulto
Feminino
Responsável: AR144.1 - CIBCHACO - Centro de Información Biomedica del Chaco


  10 / 118 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-748222
Autor: Zhang, L.; Ji, Y.X.; Jiang, W.L.; Lv, C.J..
Título: Protective roles of pulmonary rehabilitation mixture in experimental pulmonary fibrosis in vitro and in vivo
Fonte: Braz. j. med. biol. res = Rev. bras. pesqui. méd. biol;48(6):545-552, 06/2015. tab, graf.
Idioma: en.
Projeto: National Natural Science Foundation of China; . Taishan Scholar Project to Fang Han.
Resumo: Abnormal high mobility group protein B1 (HMGB1) activation is involved in the pathogenesis of pulmonary fibrosis. Pulmonary rehabilitation mixture (PRM), which combines extracts from eight traditional Chinese medicines, has very good lung protection in clinical use. However, it is not known if PRM has anti-fibrotic activity. In this study, we investigated the effects of PRM on transforming growth factor-β1 (TGF-β1)-mediated and bleomycin (BLM)-induced pulmonary fibrosis in vitro and in vivo. The effects of PRM on TGF-β1-mediated epithelial-mesenchymal transition (EMT) in A549 cells, on the proliferation of human lung fibroblasts (HLF-1) in vitro, and on BLM-induced pulmonary fibrosis in vivo were investigated. PRM treatment resulted in a reduction of EMT in A549 cells that was associated with attenuating an increase of vimentin and a decrease of E-cadherin. PRM inhibited the proliferation of HLF-1 at an IC50 of 0.51 µg/mL. PRM ameliorated BLM-induced pulmonary fibrosis in rats, with reduction of histopathological scores and collagen deposition, and a decrease in α-smooth muscle actin (α-SMA) and HMGB1 expression. An increase in receptor for advanced glycation end-product (RAGE) expression was found in BLM-instilled lungs. PRM significantly decreased EMT and prevented pulmonary fibrosis through decreasing HMGB1 and regulating RAGE in vitro and in vivo. PRM inhibited TGF-β1-induced EMT via decreased HMGB1 and vimentin and increased RAGE and E-cadherin levels. In summary, PRM prevented experimental pulmonary fibrosis by modulating the HMGB1/RAGE pathway.
Descritores: Medicamentos de Ervas Chinesas/farmacologia
Fibrose Pulmonar/tratamento farmacológico
Fibrose Pulmonar/prevenção & controle
-Antibióticos Antineoplásicos
Receptor para Produtos Finais de Glicação Avançada/efeitos dos fármacos
Apoptose/efeitos dos fármacos
Bleomicina
Western Blotting
Células Cultivadas
Colágeno/efeitos dos fármacos
Misturas Complexas/farmacologia
Medicamentos de Ervas Chinesas/uso terapêutico
Transição Epitelial-Mesenquimal/efeitos dos fármacos
Fibroblastos/efeitos dos fármacos
Proteína HMGB1/efeitos dos fármacos
Hidroxiprolina/análise
Imuno-Histoquímica
Pulmão/efeitos dos fármacos
Pulmão/patologia
Fator de Crescimento Derivado de Plaquetas/efeitos dos fármacos
Fibrose Pulmonar/patologia
Distribuição Aleatória
Ratos Sprague-Dawley
Reprodutibilidade dos Testes
Fator de Crescimento Transformador beta1/efeitos dos fármacos
Limites: Animais
Seres Humanos
Masculino
Tipo de Publ: Estudos de Avaliação
Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME



página 1 de 12 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde